Oxford Immunotec

Oxford Immunotec Announces First Patient Enrolled in REACT Trial for T-SPOT.CMV

Oxford Immunotec Reports First Quarter 2015 Financial Results

Oxford Immunotec Announces CE Mark Approval for T-SPOT.CMV Test

Oxford Immunotec Schedules First Quarter 2015 Earnings Release and Conference Call for May 5, 2015

Oxford Immunotec Announces Availability of the T-SPOT.CMV Test in the United States

Oxford Immunotec Recognizes World TB Day Through Support of the Winner of the Sir John Crofton Award

Oxford Immunotec Appoints Stephen M. Gansler as Senior Vice President and Global Head of Human Resources

Oxford Immunotec Reports Fourth Quarter and Full Year 2014 Financial Results

Oxford Immunotec to Present at the Cowen and Company 35th Annual Health Care Conference

Oxford Immunotec Schedules Fourth Quarter and Full Year 2014 Earnings Release and Conference Call for March 3, 2015

Oxford Immunotec Announces First Patients Enrolled in PROTECT Trial for T-SPOT.CMV and T-SPOT.PRT

Oxford Immunotec Global PLC Announces Closing of Underwritten Offering of Ordinary Shares and Underwriters’ Exercise of Option to Purchase Additional Shares

Oxford Immunotec Global PLC Announces Pricing of Underwritten Offering of Ordinary Shares

Oxford Immunotec Global PLC Announces Proposed Underwritten Offering of Ordinary Shares

Oxford Immunotec to Present at the 2015 Leerink Global Healthcare Conference

Oxford Immunotec Announces Completion of Re-Registration in China for T-SPOT.TB Test

Oxford Immunotec to Present at the 33rd Annual J.P. Morgan Healthcare Conference

James R. Tobin, Former CEO of Boston Scientific, Joins Oxford Immunotec Board of Directors

Oxford Immunotec to Host Technology Day

Oxford Immunotec Reports Third Quarter 2014 Financial Results

Oxford Immunotec Schedules Third Quarter 2014 Earnings Release and Conference Call for November 4, 2014

Oxford Immunotec Announces Purchase of Assets of Boulder Diagnostics Inc.

Oxford Immunotec Reports Second Quarter 2014 Financial Results

Oxford Immunotec Announces Purchase of Assets of Boulder Diagnostics Inc.

Oxford Immunotec Reports Second Quarter 2014 Financial Results

Oxford Immunotec Schedules Second Quarter 2014 Earnings Release and Conference Call for August 5, 2014

Oxford Immunotec Schedules Second Quarter 2014 Earnings Release and Conference Call for August 5, 2014

Oxford Immunotec Appoints Louis O’Dea Chief Medical Officer

Oxford Immunotec Appoints Louis O’Dea Chief Medical Officer

Oxford Immunotec Reports First Quarter 2014 Financial Results